Understanding Hyaluronan Receptor (CD44) Interaction, HA-CD44 Activated Potential Targets in Cancer Therapeutics.
Understanding Hyaluronan Receptor (CD44) Interaction, HA-CD44 Activated Potential Targets in Cancer Therapeutics.
复制标题
DOI：
10.34172/apb.2021.050
复制
发表时间：
2021-05
影响因子：
3.6
通讯作者：
Muhammad TST
中科院分区：
文献类型：
--
作者：
Chaudhry GE;Akim A;Naveed Zafar M;Safdar N;Sung YY;Muhammad TST
癌症是一种复杂的机制，涉及一系列细胞事件。透明质酸(HA)等糖蛋白是细胞外基质(ECM)的重要组成部分，参与肿瘤的发生、发展过程。HA在肿瘤进展中的关键作用依赖于在各种癌症中的异常表达。HA作为CD44受体的主要配体也引起了人们的关注。CD44是一种复杂的跨膜受体蛋白，由于转录过程中的选择性剪接，主要存在多种CD44亚型。不同的CD44亚型(CD44v)标准(CD44s)的过度表达取决于肿瘤的类型和分期。受体蛋白CD44参与多种生物学过程，包括细胞生长、凋亡、迁移和血管生成。HA-CD44相互作用触发生存通路，导致细胞增殖、侵袭，最终导致复杂的转移。配体-受体HA-CD44的相互作用和结合调节下游细胞骨架通路，参与细胞存活或死亡。因此，靶向HA、CD44(变异型和标准型)亚型和HA-CD44结合被认为是一种有吸引力的、有用的癌症治疗方法。使用各种透明质酸抑制剂，透明质酸酶(HYALs)，并利用靶向纳米递送抗癌药物和针对CD44的抗体，多肽在体外和体内都取得了良好的结果。然而，它们正在进行临床试验，结果有好有坏，这反映了靶向药物的各种修改的必要性，以及对肿瘤进展途径中潜在靶点的更好理解。
Cancer is a complex mechanism involving a series of cellular events. The glycoproteins such as hyaluronan (HA) are a significant element of extracellular matrix (ECM), involve in the onset of cancer developmental process. The pivotal roles of HA in cancer progression depend on dysregulated expression in various cancer. HA, also gain attention due to consideration as a primary ligand of CD44 receptor. The CD44, complex transmembrane receptor protein, due to alternative splicing in the transcription process, various CD44 isoforms predominantly exist. The overexpression of distinct CD44 isoforms (CD44v) standard (CD44s) depends on the tumour type and stage. The receptor proteins, CD44 engage in a variety of biological processes, including cell growth, apoptosis, migration, and angiogenesis. HA-CD44 interaction trigger survival pathways that result in cell proliferation, invasion ultimately complex metastasis. The interaction and binding of ligand-receptor HA-CD44 regulate the downstream cytoskeleton pathways involve in cell survival or cell death. Thus, targeting HA, CD44 (variant and standard) isoform, and HA-CD44 binding consider as an attractive and useful approach towards cancer therapeutics. The use of various inhibitors of HA, hyaluronidases (HYALs), and utilizing targeted Nano-delivery of anticancer agents and antibodies against CD44, peptides gives promising results in vitro and in vivo. However, they are in clinical trials with favourable and unfavourable outcomes, which reflects the need for various modifications in targeting agents and a better understanding of potential targets in tumour progression pathways.
登录
查看更多内容
影响因子：
4.7
作者：
Bellerby R;Smith C;Kyme S;Gee J;Günthert U;Green A;Rakha E;Barrett-Lee P;Hiscox S
通讯作者：
Hiscox S
影响因子：
4.5
作者：
Akima, K;Ito, H;Tatekawa, I
通讯作者：
Tatekawa, I
DOI：
10.4103/japtr.japtr_26_20
发表时间：
2020-07
影响因子：
1.4
作者：
Chaudhry GE;Akim A;Zafar MN;Abdullah MA;Sung YY;Muhammad TST
通讯作者：
Muhammad TST
影响因子：
3.8
作者：
Azevedo R;Gaiteiro C;Peixoto A;Relvas-Santos M;Lima L;Santos LL;Ferreira JA
通讯作者：
Ferreira JA
影响因子：
6.6
作者：
Bassi, P. F.;Volpe, A.;Racioppi, M.
通讯作者：
Racioppi, M.